| CAS NO: | 81103-11-9 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 询价 |
| 100mg | 询价 |
| 200mg | 询价 |
| Cas No. | 81103-11-9 |
| 别名 | 克拉霉素 |
| 化学名 | 6-((4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-((5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione |
| Canonical SMILES | CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O |
| 分子式 | C38H69NO13 |
| 分子量 | 747.95 |
| 溶解度 | ≥ 31.2 mg/mL in DMSO, ≥ 3.24 mg/mL in EtOH with ultrasonic and warming |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Clarithromycin, is a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, might build the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies. Among 28,484 medicines of clarithromycin, 2317 persons were co-presented to statins. Co-organization of CYP3A4 metabolized statins and clarithromycin was connected with a 2.11 fold expanded danger of death or hospitalization (95 % certainty interim [CI]: 1.79-2.48). This impact was clarified by age, proof of cardiovascular malady, diabetes mellitus and use of different anti-infection agents (multivariable balanced danger proportion: 1.02, 95 % CI: 0.85-1.22). The affectability examinations did not change the noteworthiness of effect. The danger for hospitalization or passing in persons accepting clarithromycin increments with age and cardiovascular disease yet is not causally connected with statin-clarithromycine co-organization. Reference: |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |